Ann Rodriguez, HMCC

Senior Manager, US Medical Affairs Project Management at Calliditas Therapeutics

Ann Rodriguez, HMCC, has a strong background in meeting planning and event management within the pharmaceutical industry. Ann currently serves as the US Project Manager, Medical Affairs at Calliditas Therapeutics. Prior to this, Ann worked as a Senior Meeting Manager at Evolution Health Group, LLC, where they successfully managed programs for Takeda Pharmaceuticals, focusing on client satisfaction and event strategies. Ann also gained valuable experience at Regeneron, where they held roles as Meetings & Conventions Planner and Associate Meeting and Conventions Planner, collaborating with key stakeholders and overseeing vendor partnerships for DUPIXENT®. Earlier in their career, Ann worked as an Associate Meeting Planner at ClinicalMind LLC and as a Conference Executive/Coordinator at Nucleus Global. With their expertise in event management and strong partnerships with key stakeholders, Ann is well-equipped to contribute to any organization's success in the pharmaceutical industry.

Ann Rodriguez, HMCC has obtained a Bachelor of Science (BS) degree in Accounting & Marketing from Hofstra University. Additionally, they hold a Bachelor of Science (BS) degree in Business Administration and Management, with a focus on General studies, from Southern New Hampshire University. The specific years of their education, such as start and end years, were not provided.

Location

New York, United States

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Calliditas Therapeutics

2 followers

Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.


Headquarters

Stockholm, Sweden

Employees

51-200

Links